ScholarIQanswers from OpenAlex & ORCID
Vernon K. Sondak
ResearcherPublications, citations & collaboration network
Vernon K. Sondak is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vernon K. Sondak have?
ScholarIQindexed works
Vernon K. Sondak has 859 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vernon K. Sondak have?
ScholarIQcitation count
Vernon K. Sondak has 36,194 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vernon K. Sondak?
ScholarIQh-index
Vernon K. Sondak has an h-index of 88 in OpenAlex.
What is the i10-index of Vernon K. Sondak?
ScholarIQi10-index
Vernon K. Sondak has an i10-index of 361 in OpenAlex.
What is the ORCID of Vernon K. Sondak?
ScholarIQorcid
The ORCID for Vernon K. Sondak is on the source record.
What is the OpenAlex record for Vernon K. Sondak?
ScholarIQopenalex
The OpenAlex for Vernon K. Sondak is on the source record.
What are the most-cited papers on Vernon K. Sondak?
ScholarIQmost cited works
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Michael B. Atkins, David R. Byrd, Antônio C. Buzaid, Alistair J. Cochran, Daniel G. Coit, Shouluan Ding, Alexander M.M. Eggermont, Keith T. Flaherty, Phyllis A. Gimotty, John M. Kirkwood, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Arthur J. Sober, Vernon K. Sondak
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John Hyngstrom, Siwen Hu‐Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach‐Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari Kendra, Richard C. Wu, Craig Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James Warneke, Alexandra P. Ikeguchi, Jose Eugenio Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy C. Hsueh, Kim Margolin, Warren Chow, Kenneth F. Grossmann, Eliana Dietrich, Víctor G. Prieto, Michael Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa A. Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, J. W. Chapman, Donna Niedzwiecki, Vera J. Suman, James Moon, Vernon K. Sondak, Michael B. Atkins, Elizabeth A. Eisenhauer, Wendy R. Parulekar, Svetomir N. Markovic, Scott Saxman, John M. Kirkwood
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
Adil Daud, Ronald C. DeConti, Stephanie Andrews, P. Urbas, Adam I. Riker, Vernon K. Sondak, Pamela N. Münster, Daniel M. Sullivan, Kenneth E. Ugen, Jane L. Messina, Richard Heller